Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
1.395
-0.085 (-5.74%)
At close: Aug 14, 2026, 4:00 PM EDT
1.380
-0.015 (-1.08%)
After-hours: Aug 14, 2026, 7:55 PM EDT

Acurx Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
10.667.563.717.479.1112.96
Cash & Short-Term Investments
10.667.563.717.479.1112.96
Cash Growth
75.73%103.85%-50.41%-17.97%-29.69%308.10%
Other Receivables
0.10.050.050.13--
Receivables
0.10.050.050.13--
Prepaid Expenses
0.230.090.10.110.260.3
Total Current Assets
10.987.693.867.719.3813.25
Total Assets
10.987.693.867.719.3813.25

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
2.830.01000.030.06
Accrued Expenses
-2.413.243.042.030.78
Total Current Liabilities
2.832.423.243.042.060.84
Total Liabilities
2.832.423.243.042.060.84

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
0000.010.010.01
Additional Paid-In Capital
87.3780.5567.9457.8745.9438.95
Retained Earnings
-79.22-75.29-67.32-53.22-38.64-26.55
Shareholders' Equity
8.155.270.624.677.3212.41
Total Liabilities & Equity
10.987.693.867.719.3813.25

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash (Debt)
10.667.563.717.479.1112.96
Net Cash Growth
75.73%103.85%-50.41%-17.97%-29.69%316.83%
Net Cash Per Share
3.955.044.5911.8016.8530.36
Filing Date Shares Outstanding
5.272.861.10.790.580.51
Total Common Shares Outstanding
4.682.350.850.720.580.51
Working Capital
8.155.270.624.677.3212.41
Book Value Per Share
1.742.240.726.4512.5824.30
Tangible Book Value
8.155.270.624.677.3212.41
Tangible Book Value Per Share
1.742.240.726.4512.5824.30
SEC Filings: 10-K · 10-Q